IQWiG finds added benefit for nivolumab in specific patients

13 September 2017
2019_biotech_test_vial_discovery_big

In recent years, nivolumab – which has been approved in Europe since June 2017 for adults with squamous cell carcinoma of the head and neck -has repeatedly been subject to early benefit assessments conducted by Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) for other oncological indications.

The IQWiG has now investigated whether the drug, marketed by US pharma major Bristol-Myers Squibb (NYSE: BMY) under the trade name Opdivo, has an added benefit for patients in a new therapeutic indication.

According to the findings, there is an indication of considerable added benefit for patients who have progressed during platinum-based chemotherapy or up to six months after completion of this treatment. No data were available for patients with later progression. Hence for these patients, an added benefit of nivolumab in comparison with the appropriate comparator therapy is not proven.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology